^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Gastroesophageal Junction Adenocarcinoma

Related cancers:
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 2 weeks - (New B)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
sintilimab
Sensitive
:
A1
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil
Sensitive
:
A2